Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16210277 | 0.79 | MAP3K12 (0.39) | — | |
| SCHEMBL31543219 | 0.79 | RAF1 (0.32) | — | |
| SCHEMBL15535335 | 0.78 | KMT2A (0.37) | CYP1A2CYP2D6MAPT | |
| SCHEMBL13738363 | 0.78 | PDE10A (0.34) | S1PR2 | |
| SCHEMBL15535054 | 0.77 | MAP3K12 (0.46) | — | |
| SCHEMBL27139379 | 0.75 | RECQL (0.37) | — | |
| SCHEMBL31224548 | 0.74 | TSHR (0.41) | S1PR2 | |
| SCHEMBL16216909 | 0.74 | BACE1 (0.34) | CYP2D6S1PR2 | |
| SCHEMBL16573747 | 0.73 | BACE1 (0.41) | CYP2D6MAPT | |
| SCHEMBL31168012 | 0.73 | CHRNB2 (0.43) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| CN-114364667-A | 3-substituted piperidines for Cbl-b inhibition and the use of Cbl-b inhibitors in combination with cancer vaccines and/or oncolytic viruses | 紐力克斯治疗公司 | 2022-04-15 | — | — | CN | disclosed |